Alpine Woods Capital Investors’s Acadia Pharmaceuticals ACAD Stock Holding History

Alpine Woods Capital Investors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-38,000	Closed	-$631K	–	211
2021 Q3	$631K	Sell	38,000 -1,000	-3%	-$19.3K	0.07%	171
2021 Q2	$951K	Hold	39,000	–	–	0.1%	158
2021 Q1	$1.01M	Hold	39,000	–	–	0.11%	157
2020 Q4	$2.08M	Hold	39,000	–	–	0.25%	115
2020 Q3	$1.61M	Hold	39,000	–	–	0.24%	121
2020 Q2	$1.89M	Hold	39,000	–	–	0.36%	84
2020 Q1	$1.65M	Hold	39,000	–	–	0.37%	79
2019 Q4	$1.67M	Hold	39,000	–	–	0.32%	76
2019 Q3	$1.4M	Sell	39,000 -10,000	-20%	-$303K	0.26%	82
2019 Q2	$1.31M	Sell	49,000 -8,000	-14%	-$204K	0.27%	90
2019 Q1	$1.53M	Sell	57,000 -10	-0%	-$234	0.33%	75
2018 Q4	$922K	Hold	57,010	–	–	0.22%	107
2018 Q3	$1.18M	Buy	57,010 +26,000	+84%	+$409K	0.24%	97
2018 Q2	$474K	Buy	31,010 +5,010	+19%	+$89.3K	0.1%	155
2018 Q1	$584K	Buy	26,000 +5,000	+24%	+$138K	0.03%	289
2017 Q4	$632K	Buy	21,000 +10,000	+91%	+$320K	0.03%	287
2017 Q3	$414K	Buy	+11,000	New	+$358K	0.02%	336

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Alpine Woods Capital Investors's ACAD Position: Q4 2021 in Review

Alpine Woods Capital Investors sold out of Acadia Pharmaceuticals (ACAD) in Q4 2021, closing a stake of 38,000 shares — an estimated $631K sold.

Alpine Woods Capital Investors first reported a position in ACAD in Q3 2017 and held it in 17 quarters. The position peaked at $2.08M in Q4 2020. 247 funds tracked by Wall St. Rank hold ACAD as of Q4 2021.

Alpine Woods Capital Investors reported no remaining Acadia Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Alpine Woods Capital Investors sold 38,000 Acadia Pharmaceuticals shares in Q4 2021, an estimated $631K.
Alpine Woods Capital Investors first reported a position in Acadia Pharmaceuticals in Q3 2017 and held it in 17 quarters.
Alpine Woods Capital Investors's Acadia Pharmaceuticals position peaked at $2.08M in Q4 2020.
247 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2021.

Based on Alpine Woods Capital Investors's 13F filing for Q4 2021, filed 3 Feb 2022.